Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
January 26, 2004
- 5 Top Products Exceed Sales of \30 Billion Each: PJ Survey
January 26, 2004
- Kyoto Univ. Invites Regional Med. Facilities to Clinical Study on ASO
January 26, 2004
- Tamiflu Should be Limited to Patients One Year of Age or Older
January 26, 2004
- OTC NEWS IN BRIEF
January 26, 2004
- Sumitomo, AstraZeneca Ink Joint Research Agreement for Respiratory Drugs
January 26, 2004
- MEDICAL DEVICE NEWS IN BRIEF
January 26, 2004
- Generic Drugs Had 13.1% Share of Ethical Sales Volume in FY2002: EPMA
January 26, 2004
- DIAGNOSTIC NEWS IN BRIEF
January 26, 2004
- Kirin's Pharma Division Aims for Sales of \70 Bil. in 2006
January 26, 2004
- Meet the Leaders (30)
January 26, 2004
- Toho to Enhance Solution Proposals to Customers
January 26, 2004
- BUSINESS NEWS IN BRIEF
January 26, 2004
- WEBSITE NEWS
January 26, 2004
- Target Approval Times for Ethical Drugs to Be Announced by April
January 26, 2004
- Korosho Studying Drug Review Update System
January 26, 2004
- Medical Expenses for 20 EBM GL-covered Diseases Account for 30% of Total, \7.3 Trillion
January 26, 2004
- OTC NEWS IN BRIEF
January 19, 2004
- Chuikyo to Resume Discussions on 80% Rule for 1st Generics
January 19, 2004
- Meet the Leaders (29)
January 19, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…